Published in Cell Death Dis on December 06, 2012
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science (2015) 2.24
Exploiting replicative stress to treat cancer. Nat Rev Drug Discov (2015) 1.27
Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov (2013) 1.25
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget (2014) 1.05
ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res (2014) 1.03
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget (2015) 0.99
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
Targeting the Checkpoint to Kill Cancer Cells. Biomolecules (2015) 0.94
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol (2013) 0.93
Molecular Pathways: Targeting ATR in Cancer Therapy. Clin Cancer Res (2015) 0.90
Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res (2015) 0.90
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res (2014) 0.89
A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLoS One (2015) 0.89
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. Biomolecules (2015) 0.88
Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiat Environ Biophys (2013) 0.88
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol (2015) 0.86
rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis. Oncotarget (2015) 0.85
Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. Br J Cancer (2014) 0.84
DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Semin Radiat Oncol (2015) 0.84
Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol Oncol (2015) 0.83
Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer (2014) 0.83
APOBEC3A damages the cellular genome during DNA replication. Cell Cycle (2016) 0.83
ATR Kinase Inhibition Protects Non-cycling Cells from the Lethal Effects of DNA Damage and Transcription Stress. J Biol Chem (2016) 0.82
Development of synthetic lethality anticancer therapeutics. J Med Chem (2014) 0.82
Coupling of Homologous Recombination and the Checkpoint by ATR. Mol Cell (2016) 0.81
Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep (2017) 0.81
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J Gastroenterol (2016) 0.78
DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer. DNA Repair (Amst) (2016) 0.77
REV1 is important for the ATR-Chk1 DNA damage response pathway in Xenopus egg extracts. Biochem Biophys Res Commun (2015) 0.77
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. Cell Rep (2015) 0.77
Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents. Cell Cycle (2014) 0.76
Targeting chromatin to improve radiation response. Br J Radiol (2014) 0.76
Cell-free Xenopus egg extracts for studying DNA damage response pathways. Int J Dev Biol (2016) 0.76
Non-thermal plasma-induced apoptosis is modulated by ATR- and PARP1-mediated DNA damage responses and circadian clock. Oncotarget (2016) 0.75
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiother Oncol (2016) 0.75
Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) (2016) 0.75
Requirement of ATR for maintenance of intestinal stem cells in aging Drosophila. Aging (Albany NY) (2015) 0.75
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun (2017) 0.75
TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation. Mol Cancer Ther (2016) 0.75
The cell cycle checkpoint inhibitors in the treatment of leukemias. J Hematol Oncol (2017) 0.75
A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers. Oncotarget (2016) 0.75
ATR maintains chromosomal integrity during postnatal cerebellar neurogenesis and is required for medulloblastoma formation. Development (2016) 0.75
Local DNA repair inhibition for sustained radiosensitization in high grade gliomas. Mol Cancer Ther (2017) 0.75
DNA damage-induced ATR kinase activation in non-replicating cells is regulated by the XPB subunit of transcription factor II-H (TFIIH). J Biol Chem (2017) 0.75
LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma. J Pharm Biomed Anal (2017) 0.75
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun (2017) 0.75
Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta (2017) 0.75
GBM radiosensitizers: dead in the water…or just the beginning? J Neurooncol (2017) 0.75
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Pancreatic cancer. N Engl J Med (2010) 13.88
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer (2011) 4.08
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol (2007) 3.86
Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol (2009) 3.67
Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell (2008) 3.15
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol (2011) 3.10
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol (2011) 2.85
ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A (2001) 2.75
A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet (2009) 2.68
Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res (1998) 2.63
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res (2010) 1.82
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem (2011) 1.67
Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell (2005) 1.60
ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem (2001) 1.59
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res (2008) 1.53
Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat Genet (2009) 1.51
Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg (2011) 1.47
Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest (2011) 1.46
ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet (2009) 1.43
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer (2011) 1.39
Characterization of radiation-induced apoptosis in the small intestine and its biological implications. Int J Radiat Biol (1994) 1.38
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther (2012) 1.35
Morphologic response of the mucosa of human small intestine to x-ray exposure. J Clin Invest (1966) 1.35
Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res (2011) 1.30
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res (2009) 1.25
The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amst) (2004) 1.25
Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther (2007) 1.24
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer (2012) 1.15
Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res (2005) 1.13
Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle (2009) 1.11
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol (2012) 1.11
ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene (2011) 1.09
The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol (2010) 1.09
Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer Res (2011) 0.94
Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist (2012) 0.92
Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol (2011) 0.89
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res (2004) 0.87
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med (2001) 5.52
Nutritional rickets in African American breast-fed infants. J Pediatr (2000) 4.76
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med (2000) 4.36
Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology (2007) 2.99
Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol (1999) 2.36
LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol (2001) 2.07
Amplification of nitric oxide signaling by interstitial cells isolated from canine colon. Proc Natl Acad Sci U S A (1993) 1.77
Dissection of the fusarium I2 gene cluster in tomato reveals six homologs and one active gene copy. Plant Cell (1998) 1.76
Apoptosis: an early event in metastatic inefficiency. Cancer Res (2001) 1.74
Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res (2001) 1.71
The Ras radiation resistance pathway. Cancer Res (2001) 1.59
Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem (1999) 1.58
On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol (2011) 1.58
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem (2000) 1.57
Isolation of variants in phagocytosis of a macrophage-like continuous cell line. J Exp Med (1977) 1.54
Glutathione deficiency and radiosensitivity in AIDS patients. Lancet (1991) 1.51
Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A (1994) 1.50
Neuroblastoma--when are urinary catecholamines and their metabolites 'normal'? Ann Clin Biochem (1988) 1.48
Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res (2000) 1.43
Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis (1995) 1.42
Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene (1997) 1.42
Cell cycle-dependent regulation of the cyclin B1 promoter. J Biol Chem (1995) 1.36
Evidence for post-transcriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells. EMBO J (1995) 1.31
The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol (1994) 1.31
Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am J Pathol (1985) 1.28
Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res (1990) 1.27
Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res (1996) 1.27
92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor. Am J Pathol (1995) 1.26
Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res (1987) 1.20
Effects of ionizing radiation on cell cycle progression. A review. Radiat Environ Biophys (1995) 1.16
Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Am J Pathol (2000) 1.15
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer (2012) 1.15
Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway. Oncogene (2006) 1.14
HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle. Proc Natl Acad Sci U S A (1998) 1.14
Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res (1998) 1.12
The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res (1996) 1.11
Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res (1998) 1.09
Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett (2007) 1.09
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer (2011) 1.08
Retraction of data on the human c-ras1H oncogene. Science (1983) 1.07
Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res (1990) 1.05
Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis (1992) 1.05
Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene (2007) 1.04
The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res (2001) 1.04
Cyclin B1 availability is a rate-limiting component of the radiation-induced G2 delay in HeLa cells. Cancer Res (1997) 1.03
Distribution of lymphatic vessels in normal and arthritic human synovial tissues. Ann Rheum Dis (2003) 1.03
Cell cycle-dependent usage of transcriptional start sites. A novel mechanism for regulation of cyclin B1. J Biol Chem (1998) 1.02
Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc Natl Acad Sci U S A (1998) 1.01
Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett (2001) 1.01
Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol (1994) 1.01
The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys (1990) 1.01
Modulation of Fc-mediated phagocytosis by cyclic AMP and insulin in a macrophage-like cell line. J Immunol (1977) 1.00
Stable expression of rabies virus glycoprotein in Chinese hamster ovary cells. J Gen Virol (1991) 0.99
Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol (1998) 0.98
Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. Oncogene (1996) 0.97
Properties of protein kinase and adenylate cyclase-deficient variants of a macrophage-like cell line. J Cell Physiol (1979) 0.96
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Br J Cancer (2005) 0.95
Expression trapping: identification of novel genes expressed in hematopoietic and endothelial lineages by gene trapping in ES cells. Blood (1998) 0.95
Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α. Oncogene (2011) 0.93
Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci (1994) 0.93
Potential molecular targets for manipulating the radiation response. Int J Radiat Oncol Biol Phys (1997) 0.93
Delayed cyclin B1 expression during the G2 arrest following DNA damage. Oncogene (1996) 0.92
Specific cleavage of gamma catenin by caspases during apoptosis. FEBS Lett (1998) 0.92
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res (2000) 0.91
A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer (2005) 0.91
Predictive value of femoral head heterogeneity for fracture risk. Bone (2009) 0.91
Developmental expression of MMP-9 (gelatinase B) mRNA in mouse embryos. Dev Dyn (1995) 0.90
MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. Brain Res Dev Brain Res (1995) 0.90
The effect of E1A transfection on MMP-9 expression and metastatic potential. Int J Cancer (1995) 0.89
Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs (2001) 0.89
Serum dopamine beta hydroxylase in children with neuroblastoma. Br J Cancer (1983) 0.89
Induction and repair of DNA double strand breaks in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. Cancer Res (1990) 0.88
tRNA-like properties of tobacco rattle virus RNA. Nucleic Acids Res (1987) 0.88
Calcium channel and membrane fusion activity of synexin and other members of the Annexin gene family. Biophys J (1992) 0.88
Cyclin A message stability varies with the cell cycle. Cell Growth Differ (1997) 0.88
Increased G2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. Radiat Res (1991) 0.88
The rapid purification and partial characterization of human serum angiotensinogen. Biochem J (1987) 0.87
Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clin Exp Metastasis (2000) 0.87
Reducing the radiation-induced G2 delay causes HeLa cells to undergo apoptosis instead of mitotic death. Int J Radiat Biol (1996) 0.87
Interactive effect of reduced pollen availability and Varroa destructor infestation limits growth and protein content of young honey bees. J Insect Physiol (2013) 0.85
DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers. Br J Cancer (2007) 0.85
Ras, metastasis, and matrix metalloproteinase 9. Methods Enzymol (2001) 0.85
'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer (1999) 0.85
p34(Cdc2) kinase activity is excluded from the nucleus during the radiation-induced G(2) arrest in HeLa cells. J Biol Chem (1999) 0.84
The effects of radiation on the expression of a newly cloned and characterized rat cyclin B mRNA. Int J Radiat Oncol Biol Phys (1994) 0.84
Ras regulation of radioresistance in cell culture. Methods Enzymol (2001) 0.83
Can γH2AX be used to personalise cancer treatment? Curr Mol Med (2013) 0.83
Cyclin expression and G2-phase delay after irradiation. Radiat Res (1994) 0.82
Distress associated with radiotherapy for malignant disease: a quantitative analysis based on patients perceptions. Br J Cancer (1989) 0.82
Radiation and the G2 phase of the cell cycle. Radiat Res (1998) 0.81
A non-catalytic role of choline kinase alpha is important in promoting cancer cell survival. Oncogenesis (2013) 0.81